Tau, synapse loss and gliosis progress in an Alzheimer’s mouse model after amyloid-β immunotherapy
Brain · 03.04.2025 · 148 (4) · 1316-1328
DOI: 10.1093/brain/awae345 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 06.11.2024. Verfasst von Lindsay A Welikovitch und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Massachusetts General Hospital, Charlestown, MA 02129, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Gliosis, Synapses, tau Proteins. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CIHR, NIA NIH HHS, Fonds de recherche du Québec - Santé.
Themen: Demenz
Abstract (Originalsprache)
Preclinical studies assessing drugs for Alzheimer’s disease (AD) are conducted in animal models that usually display only one neuropathological feature of AD, whereas patients present with a complex combination of comorbidities and neuropathologies. Importantly, it is well established that amyloid-β (Aβ) plaque and tau tangle accumulation interact in a phase-dependent manner, making it difficult to predict how targeting one might influence the other, as well as downstream degeneration. We developed a transgenic mouse model, APP/PS1xTau22, with progressive cortical Aβ deposition and hippocampal tau neurofibrillary inclusions, to investigate how both neuropathologies act jointly to bring about neural degeneration, synapse loss and glial phenotypes. We then assessed whether applying murine chimeric aducanumab, an anti-amyloid immunotherapy, could impact the synergistic relationship between amyloid and tau. Drug treatment resulted in a ∼70% reduction in Aβ deposition in hippocampal and cortical areas and produced a robust peri-plaque microglial and astrocytic response. Removing amyloid from the brain did not reverse or slow tau pathology or alter synapse loss. Our findings suggest that, once the interaction between amyloid and tau is set in motion, reducing plaque burden by Aβ immunotherapy may stimulate glial responses, but is insufficient to curb degenerative phenotypes in this model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Massachusetts General Hospital, Charlestown, MA 02129, USA.
- Harvard Medical School, Harvard University, Boston, MA 02115, USA.
- University of Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition Lille, F-59000 Lille, France.
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
- Research and Development, Biogen, Cambridge, MA 02142, USA.
ORCID-Profile: Luc Buée, Lori B Chibnik
Förderung
- CIHR
- NIA NIH HHS
- Fonds de recherche du Québec - Santé
- JPB Foundation
- Rainwater Foundation
- NIH HHS
- Alzheimer's Association
- Fonds de recherche du Québec – Santé
Zitieren
APA
Welikovitch, L. A., Mate de Gerando, A., Khasnavis, A., Bhavsar, H., Meltzer, J. C., Buée, L., Chibnik, L. B., Bussiere, T., & Hyman, B. T. (2025). Tau, synapse loss and gliosis progress in an Alzheimer’s mouse model after amyloid-β immunotherapy. Brain, 148(4), 1316-1328. https://doi.org/10.1093/brain/awae345
Vancouver
Welikovitch LA, Mate de Gerando A, Khasnavis A, Bhavsar H, Meltzer JC, Buée L, et al. Tau, synapse loss and gliosis progress in an Alzheimer’s mouse model after amyloid-β immunotherapy. Brain. 2025;148(4):1316-1328. doi:10.1093/brain/awae345
BibTeX
@article{Welikovitch2025,
author = {Welikovitch, Lindsay A and Mate de Gerando, Anastasie and Khasnavis, Anita and Bhavsar, Harshil and Meltzer, Jonah C and Buée, Luc and Chibnik, Lori B and Bussiere, Thierry and Hyman, Bradley T},
title = {Tau, synapse loss and gliosis progress in an Alzheimer’s mouse model after amyloid-β immunotherapy},
journal = {Brain},
year = {2025},
volume = {148},
number = {4},
pages = {1316--1328},
doi = {10.1093/brain/awae345}
}
EUVIMED